Mirae Asset Global Investments Co., Ltd. Revance Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,496 shares of RVNC stock, worth $8,984. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,496

Previous 3,791 7.78%

Holding current value

$8,984

Previous $9,000 11.11%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	N/A	-295 Reduced 7.78%	3,496 $8,000
Q3 2024 Oct 23, 2024	BUY	$2.57 - $2.57 $1,729 - $1,729	673 Added 21.58%	3,791 $9,000
Q2 2024 Jul 30, 2024	SELL	$2.34 - $4.73 $80,730 - $163,185	-34,500 Reduced 91.71%	3,118 $8,000
Q1 2024 May 01, 2024	SELL	$4.65 - $9.31 $1,883 - $3,770	-405 Reduced 1.07%	37,618 $185,000
Q4 2023 Jan 24, 2024	BUY	$5.81 - $11.2 $732 - $1,411	126 Added 0.33%	38,023 $334,000
Q3 2023 Oct 26, 2023	BUY	$11.47 - $25.07 $1,904 - $4,161	166 Added 0.44%	37,897 $434,000
Q2 2023 Aug 10, 2023	BUY	$24.7 - $37.61 $17,018 - $25,913	689 Added 1.86%	37,731 $954,000
Q1 2023 May 04, 2023	SELL	$18.36 - $35.27 $734 - $1,410	-40 Reduced 0.11%	37,042 $1.19 Million
Q4 2022 Feb 09, 2023	BUY	$18.32 - $30.66 $100,631 - $168,415	5,493 Added 17.39%	37,082 $684,000
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $142,784 - $283,675	9,964 Added 46.08%	31,589 $853,000
Q2 2022 Jul 26, 2022	BUY	$11.52 - $20.4 $249,120 - $441,149	21,625 New	21,625 $299,000

Others Institutions Holding RVNC

# of Institutions

226

Shares Held

82.6M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Revance Therapeutics, Inc. Transaction History